R&D Investment By Pharmaceutical Companies Tops $38 Billion In 2004
New statistics released show that PhRMA's biotechnology and pharmaceutical research member companies invested a record $38.8 billion in research and development on medicines in 2004 (up from $34.5 billion in 2003). This tops a steady increase in R&D over more than two decades, from an estimated investment of $2 billion in 1980.
The growth in R&D continues to support important advances by research scientists and physicians that bring better medical treatments to patients, with a growing focus on biologics (treatments generated from living materials such as venom or bacteria). The biopharmaceutical industry is the most research-intensive major industry in the United States and the U.S. greatly exceeds Europe in biopharmaceutical R&D investment.
The $38.8 billion invested in R&D represents a 12.6 percent increase over expenditures in 2003 and is more than four-and-a-half times the investment in 1990. Of this $38.8 billion, PhRMA member companies spent an estimated $30.6 billion in R&D within the United States, and an estimated $8.2 billion in R&D conducted abroad. PhRMA member companies spent an estimated 18.8 percent of domestic sales on R&D within the United States.
"I am proud that the U.S. biopharmaceutical industry is America's most research-intensive industry and is the world's largest source of investment in discovering better treatments, exceeding the international pharmaceutical industry and the National Institutes of Health. The human and economic cost of disease is too high and new medicines are needed to reduce those costs," said PhRMA president and CEO Billy Tauzin.
Most read news
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.